Open Question
Abbott Labs just reported good earnings and reaffirmed guidance for the year,
but the stock has not been performing well all year. It seems stuck. Why?
Page 1 of 1
There's just no desire to own this sector right now. Not every name in the group
is a winner, but neither dividend yields, valuation or the few names with decent
pipelines seem to be generating much investor interest.
I don't know ABT as well as some other names in the group, but if you're right
about solid fundamentals and you can be patient, there will be a time not too
long from now when folks will rotate back into the pharma sector.
Rate Now:
Average Rating: 0.00 / 0
Page 1 of 1